ArticleJournal of thoracic disease2026

Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study.

Haoyu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.